Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03531645
Recruitment Status : Active, not recruiting
First Posted : May 22, 2018
Last Update Posted : May 9, 2022
Eli Lilly and Company
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : September 30, 2025